Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPDGlobeNewsWire • 07/03/24
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJMGlobeNewsWire • 06/26/24
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVCBenzinga • 06/26/24
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi's Executive CommitteeGlobeNewsWire • 06/21/24
Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiranGlobeNewsWire • 06/21/24
Belharra Therapeutics Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Small Molecule Therapeutics for Immunological DiseasesGlobeNewsWire • 06/18/24
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona StocksInvestors Business Daily • 06/13/24
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3GlobeNewsWire • 06/03/24
FDA extends deadline, requests more data on Sanofi's Dupixent for treating 'smoker's lung'Reuters • 05/31/24
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDGlobeNewsWire • 05/31/24
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationGlobeNewsWire • 05/31/24